Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | LITAF | Q99732 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041080 | 0.98 | TSHR (0.46) | TSHRMEN1KMT2AUSP2HPGD | |
| SCHEMBL7041077 | 0.93 | TSHR (0.43) | TSHRMEN1KMT2AUSP2HPGD | |
| SCHEMBL656323 | 0.92 | MDM2 (0.48) | TSHRMEN1KMT2AMDM2PAK1 | |
| SCHEMBL656324 | 0.92 | MDM2 (0.48) | TSHRMEN1KMT2AMDM2PAK1 | |
| SCHEMBL24424726 | 0.79 | L3MBTL1 (0.60) | TP53USP30L3MBTL1EGFRSRC | |
| SCHEMBL4418493 | 0.79 | L3MBTL1 (0.60) | TP53USP30L3MBTL1EGFRSRC | |
| SCHEMBL4411954 | 0.79 | L3MBTL1 (0.60) | TP53USP30L3MBTL1EGFRSRC | |
| SCHEMBL1025817 | 0.73 | TMEM97 (0.54) | MEN1KMT2AHSD17B10USP30L3MBTL1 | |
| SCHEMBL1029343 | 0.72 | L3MBTL1 (0.70) | TSHRKMT2ASTSTP53L3MBTL1 | |
| SCHEMBL31352046 | 0.72 | L3MBTL1 (0.70) | TSHRKMT2ASTSTP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | TSHR 972/4885MEN1 4716/4885KMT2A 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.